Vaccine Studied at Yale Could Delay, Cure Cancer in Dogs

Yale School of Medicine immunologist Dr. Mark Mamula is leading groundbreaking research on a cancer vaccine for dogs through his company, Therajan, offering new hope to pet owners nationwide. Now in clinical trials, the vaccine can attack, delay, and in some cases cure certain cancers in dogs, which affect one in four canines—especially high-risk breeds like golden retrievers. The treatment is delivered in an innovative mobile veterinary setup, with vets meeting owners in parking lots across New York and Connecticut.

Dogs receive two doses, spaced three weeks apart, and are closely monitored for progress. Early detection is key, as lower disease levels improve outcomes. Local veterinarian Dr. Lindsay Thalheim is among those administering the vaccine, emphasizing its potential impact. Owners, like Danette Dykema of Preston, whose dog Tybee recently received his first dose, express deep gratitude for the opportunity, calling the treatment a life-changing breakthrough in the fight against canine cancer.